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Abstract
Aims Mineralocorticoid receptor antagonists (MRAs) have been demonstrated to improve outcomes in reduced ejection frac-
tion heart failure (HFrEF) patients. However, MRAs added to conventional treatment may lead to worsening of renal function
and hyperkalaemia. We investigated, in a population-based analysis, the long-term effects of MRA treatment in HFrEF patients.
Methods and results We analysed data of 6046 patients included in the Metabolic Exercise Cardiac Kidney Index score
dataset. Analysis was performed in patients treated (n = 3163) and not treated (n = 2883) with MRA. The study endpoint
was a composite of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation. Ten years’
survival was analysed through Kaplan–Meier, compared by log-rank test and propensity score matching.
At 10 years’ follow-up, the MRA-untreated group had a signiﬁcantly lower number of events than the MRA-treated group
(P < 0.001). MRA-treated patients had more severe heart failure (higher New York Heart Association class and lower left ven-
tricular ejection fraction, kidney function, and peak VO2). At a propensity-score-matching analysis performed on 1587 patients,
MRA-treated and MRA-untreated patients showed similar study endpoint values.
Conclusions In conclusion, MRA treatment does not affect the composite of cardiovascular death, urgent heart transplanta-
tion or left ventricular assist device implantation in a real-life setting. A meticulous patient follow-up, as performed in trials, is
likely needed to match the positive MRA-related beneﬁts observed in clinical trials.
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Introduction
The sustained activation of the renin–angiotensin–
aldosterone system is inappropriate and pathologic in pa-
tients with chronic heart failure (HF) with reduced ejection
fraction (HFrEF).1 Treatment with mineralocorticoid receptor
antagonists (MRAs) has been demonstrated to improve clini-
cal outcomes in patients with HFrEF with mild to severe
symptoms and also in patients with left ventricular dysfunc-
tion after myocardial infarction.2–4 The beneﬁt of the addi-
tion of MRA to an HF treatment regimen has been
demonstrated in a few multicentre, large-sized, placebo-
controlled randomized well-conducted studies and speciﬁ-
cally in the Randomized Aldactone Evaluation Study (RALES)
trial,2 in the Eplerenone Post-Acute Myocardial Infarction
Heart Failure Efﬁcacy and Survival Study (EPHESUS),3 and ﬁ-
nally, in the Eplerenone in Mild Patients Hospitalization and
Survival Study in Heart Failure (EMPHASIS-HF).4
In patients with HFrEF, MRA added to conventional treat-
ment may lead to worsening of renal function (WRF) and to
serious and, occasionally, life-threatening hyperkalaemia
(HK).5–8 Data from the EPHESUS trial showed that early
WRF with eplerenone was associated with an increased risk
of adverse cardiovascular outcomes, yet the beneﬁt of
eplerenone was maintained.9 However, the prognostic signif-
icance of WRF and HK in real-life patients with moderate to
severe HF receiving MRA remains unknown, albeit some re-
ports showed an increase in hospitalization rate due to
WRF and/or HK.10
The aim of the present study was to investigate, in a
population-based analysis, the long-term effects of MRA
treatment in patients affected by HFrEF. To do so, we
analysed data of the Metabolic Exercise Cardiac Kidney Index
(MECKI) score research group, which consists of a sizable
population of HFrEF patients.
Methods
Population and study procedures
We collected and analysed data of a cohort of 6112 patients
with a history of HFrEF, enrolled and prospectively followed
in 23 Italian HF centres participating in the MECKI score re-
search group. Part of the study population (n = 2715) was de-
rived from the MECKI score validation study11 but with an
updated follow-up. The remaining patients were derived
from a recruitment extension of the MECKI score database
(n = 3397). From the total population of 6112 patients, we se-
lected those with complete treatment information in terms
of MRA (n = 6110) and excluded patients with a contraindica-
tion to MRA treatment due to estimated glomerular ﬁltration
rate < 30 mL/min/1.73 m2 (n = 64),12 with a ﬁnal population
of 6046 subjects (Figure 1). In brief, criteria at enrolment
were previous or present HF symptoms (functional New York
Heart Association, NYHA, Classes I–IV, Stages B and C of
American College of Cardiology/American Heart Association
classiﬁcation) and former documentation of a reduced left
ventricular ejection fraction (LVEF <40%), unchanged HF
medications for at least 3 months, ability to perform a cardio-
pulmonary exercise test (CPET), and no major cardiovascular
treatment or intervention scheduled. As exclusion criteria,
we considered history of pulmonary embolism, moderate to
severe aortic and mitral stenosis, pericardial disease, severe
obstructive lung disease, exercise-induced angina and signiﬁ-
cant electrocardiography (ECG) alterations, or presence of
any clinical co-morbidity interfering with exercise perfor-
mance. At enrolment, clinical history and therapy information
were recorded, and then physical examination, laboratory
analyses, ECG, transthoracic echocardiography, and CPET
were performed, as previously described.11
To assess the prognostic role of MRA in HF, data analysis
was performed in the two groups, patients treated and un-
treated with MRA. The study endpoint was the composite
of cardiovascular death, urgent heart transplantation deﬁned
as United Network for Organ Sharing Status 1,13 or left ven-
tricular assist device (LVAD) implantation.
Follow-up and data management
Patients’ follow-up and procedures of data management
were performed as previously reported.11 In brief, follow-up
was carried out according to the local HF programme and
ended with the last clinical evaluation or with patients’ death,
urgent heart transplantation, or LVAD implantation.11 If a
Figure 1 Study population and data analysis. From the whole population
of 6112 patients, we selected those with complete treatment information
as regards presence or not of mineralocorticoid receptor antagonist
(MRA) treatment (n = 6110). Afterwards, we excluded patients with con-
traindication to MRA due to estimated glomerular ﬁltration rate
(eGFR) < 30 mL/min/1.73 m2. The ﬁnal analysed population was com-
posed of 6046 subjects, including 2883 MRA-untreated and 3163 MRA-
treated patients.
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patient died outside the hospital where he or she was
followed up, medical records of the event and reported cause
of death were considered.
Statistical analysis
Continuous variables are presented as mean ± standard devi-
ation and were compared between groups using the t-test for
independent samples. Categorical variables are reported as
frequency and percentage, and they were compared using
the χ2 test. The association between use of MRA and end-
point (composite of cardiovascular death, urgent cardiac
transplant, or LVAD implantation) was assessed by Kaplan–
Meier analysis and groups compared by log-rank test.
To reduce the treatment selection bias due to confounding
variables, a propensity-score-matching analysis was per-
formed. The following variables were considered: age, gen-
der, MECKI score, year of enrolling and centre where
enrolment was done, NYHA functional class, LVEF, oxygen
uptake at peak exercise (peak VO2 expressed as millilitres
per minute per kilogram), systolic blood pressure, serum cre-
atinine (log), haemoglobin, serum sodium (Na+), presence of
implantable cardioverter deﬁbrillator, and drug treatments
with beta-blockers, angiotensin-converting enzyme inhibi-
tors, angiotensin II receptor blockers, diuretic, statins, antico-
agulant treatment, digitalis, and amiodarone. Each MRA user
was matched to a non-MRA user by applying a nearest-
neighbour matching analysis with 0.01 calliper. In order to
validate the results obtained with the propensity score
matching, we run different analyses according to the strategy
proposed by Martens et al.14: (1) Cox regression on the orig-
inal dataset, adjusting for all the covariates employed in the
propensity score matching; (2) Cox regression on the original
dataset, using propensity score as a covariate; and (3) Cox
regression on the original dataset, stratiﬁed for propensity
score. The hazard ratios (HRs) obtained with the different
approaches were then compared with the HRs of an unad-
justed Cox regression run on propensity-score-matched data.
In order to correct for slight imbalances in propensity score,
Cox regression analysis, adjusted for propensity score, was
employed. Several subgroup analyses were conducted by
Cox regression on propensity-score-matched data. A P value
<0.05 was considered statistically signiﬁcant. All data were
collected in an Excel database, and analyses were performed
using SAS Version 9.4 (SAS Institute, Cary, North Carolina).
Results
Patient population
A total of 6046 HF patients (82% male, mean age
61.3 ± 12.7 years) fulﬁlled the study inclusion/exclusion
criteria and were included in the present analysis. Mean LVEF
of the entire population was 33 ± 10.5%; 72% were in NYHA
Classes I and II and 28% in Classes III and IV; mean peak VO2
was 14.8 ± 4.8 mL/min/kg; HF aetiology was an ischaemic car-
diomyopathy in 46%, an idiopathic dilated cardiomyopathy in
40%, a valvular cardiomyopathy in 5%, and other in 10%. A
total of 3163 patients (52%) were on MRA while the remain-
ing 2883 (48%) were not treated with MRA. MRA-treated pa-
tients had more severe HF (Table 1). At study run-in, 351
patients (185 MRA treated and 166 MRA untreated) had
K+ > 5.0 meq/L.12
Table 1 Characteristics of patients not treated and treated with
MRA
MRA
(n = 2883)
MRA+
(n = 3163) P
Age (years) 61.3 ± 13.4 61.4 ± 12.2 0.6504
BMI (kg/m2) 26.7 ± 4.3 26.8 ± 4.4 0.3745
LVEF (%) 35.6 ± 10.9 31.0 ± 9.6 <0.0001
SBP (mmHg) 120.4 ± 17.2 114.4 ± 17.2 <0.0001
HR at rest (b.p.m.) 69.9 ± 12.0 71.6 ± 12.8 <0.0001
Peak VO2 (mL/min/kg) 15.5 ± 5.2 14.2 ± 4.4 <0.0001
Peak VO2 (% of
predicted)
58.6 ± 17.8 53.7 ± 16.7 <0.0001
Peak HR (b.p.m.) 121.6 ± 25.3 117.4 ± 24.2 <0.0001
VE/VCO2 slope 31.8 ± 7.1 33.6 ± 8.2 <0.0001
MDRD (mL/min/1.73 m2) 72.5 ± 24.1 70.5 ± 23.7 0.0011
Hb (g/dL) 13.5 ± 1.6 13.4 ± 1.6 0.0023
Gender (n, %)
Female 553 (19.2) 555 (17.5) 0.1008
Male 2330 (80.8) 2608 (82.5)
NYHA (n, %) <0.0001
I 533 (18.5) 381 (12.1)
II 1753 (60.8) 1664 (52.6)
III 576 (20.0) 1062 (33.6)
IV 21 (0.7) 54 (1.7)
Atrial ﬁbrillation (n, %) 396 (13.7) 561 (17.8) <0.0001
ICD (n, %) 667 (23.1) 1216 (38.5) <0.0001
CRT (n, %) 239 (8.4) 503 (16.1) <0.0001
Aetiology (n, %) 0.0005
Idiopathic 1109 (38.7) 1265 (40.4)
Ischaemic 1285 (44.9) 1476 (47.1)
Valvular 144 (5.0) 126 (4.0)
Other 325 (11.4) 268 (8.5)
ACE inhibitors (n, %) 2132 (73.9) 2393 (75.7) 0.1269
ARBs (n, %) 533 (18.5) 585 (18.5) 0.9941
Diuretics (n, %) 1989 (69.0) 2857 (90.3) <0.0001
Statins (n, %) 1197 (41.7) 1504 (47.9) <0.0001
Allopurinol (n, %) 603 (21.0) 955 (30.4) <0.0001
Beta-blockers (n, %) 2419 (83.9) 2833 (89.6) <0.0001
Antiplatelets (n, %) 1543 (53.5) 1708 (54) 0.7092
Oral anticoagulants
(n, %)
719 (24.9) 1072 (33.9) <0.0001
Amiodarone (n, %) 602 (20.9) 878 (27.8) <0.0001
Digitalis (n, %) 505 (17.5) 710 (22.5) <0.0001
Potassium (meq/L) 4.3 ± 0.5 4.3 ± 0.5 0.6483
Sodium (mmol/L) 139.7 ± 3.1 139 ± 3.4 <0.0001
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor
blockers; BMI, body mass index; CRT, cardiac resynchronization
therapy; Hb, haemoglobin; HR, heart rate; ICD, implantable
cardioverter deﬁbrillator; LVEF, ejection fraction; MDRD, Modiﬁca-
tion of Diet in Renal Disease; MRA, mineralocorticoid receptor an-
tagonists; NYHA, New York Heart Association; Peak VO2, oxygen
uptake at peak exercise; SBP, systolic blood pressure; VE/VCO2
slope, minute ventilation/carbon dioxide production relationship.
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Follow-up
For the total population, the median follow-up period
was 3.7 years (interquartile range 1.7–6.4), while it was 3.5
(interquartile range 1.6–6.1) and 3.9 years (interquartile
range 1.8–6.7) in patients receiving and not receiving MRA
treatment, respectively. The events occurring at 10 year
follow-up were 1042: 46 events person/year * 1000 in
MRA-treated patients vs. 34 events person/year * 1000
(P-value < 0.0001) in the MRA-untreated patients. At
10 years’ follow-up, the MRA-untreated group had signiﬁ-
cantly higher freedom from events than the MRA-treated
group (log-rank test, P < 0.001) (Figure 2). The MRA-
untreated group had 370 cardiovascular deaths, 67 urgent
heart transplants, and 1 LVAD implantation, while the MRA-
treated group had 506 cardiovascular deaths, 87 urgent heart
transplants, and 11 LVAD implantations. In analogy with the
RALES,2 we also analysed the study endpoint truncating the
follow-up at 2 years, but, as for the 10 years’ follow-up eval-
uation, MRA-treated patients had more events than MRA-
untreated patients.
Propensity score analysis
Propensity score matching allowed us to identify 1587
patients in both study groups, with a follow-up of 3.8
(1.8–6.5) and 3.7 (1.8–6.4) years for patients not receiving
MRA and those receiving MRA, respectively (Table 2). At
10 years’ follow-up, no differences as regards study
endpoints were observed between the two groups (Figure 3).
Similarly, no difference between groups was observed,
truncating the follow-up at 2 years. The validity of the results
of the propensity score matching was tested by applying
different analytical approaches (Table 3). In all analyses, the
HRs for the combined endpoint comparing MRA+ vs. MRA
subjects were remarkably stable, ranging from 1.13 to 1.15.
Further analysis
All the previous analyses have been performed also excluding
subjects with K+ > 5.0 meq/L but without any signiﬁcant
difference. Furthermore, supplementary analysis were
performed to evaluate MRA treatment effects in different
subgroups of HFrEF patients and speciﬁcally deﬁned accord-
ing to gender, LVEF, NYHA class, HF aetiology, peak VO2,
serum K+, drug treatment, kidney function and systolic blood
Figure 2 Kaplan–Meier analyses of study endpoint (cardiovascular death,
urgent heart transplant, or left ventricular assist device implantation) of
the mineralocorticoid receptor antagonist (MRA)-treated (MRA+) and
MRA-untreated (MRA) patients: at 10 years’ follow-up the MRA
group had signiﬁcantly higher survival than the MRA+ group
(P < 0.001). HR, hazard ratio.
Table 2 Characteristics of patients not treated and treated with
MRA in propensity-score-matching analysis
MRA
(n = 1587)
MRA+
(n = 1587) P
Age (years) 62.6 ± 13 62.6 ± 12.4 0.92
BMI (kg/m2) 26.9 ± 4.3 27.1 ± 4.5 0.36
LVEF (%) 34.2 ± 9.9 34.3 ± 9.8 0.70
SBP (mmHg) 118.1 ± 16.7 117.6 ± 17.1 0.40
HR at rest (b.p.m.) 70.3 ± 12.4 70.9 ± 12.7 0.13
Peak VO2 (mL/min/kg) 14.8 ± 4.7 14.8 ± 4.6 0.95
Peak VO2 (% of predicted) 57.1 ± 17.2 57 ± 16.9 0.92
Peak HR (b.p.m.) 118.7 ± 25.8 118 ± 24.4 0.46
VE/VCO2 slope 32.5 ± 7.3 32.6 ± 7.3 0.75
MDRD (mL/min/1.73 m2) 72.2 ± 24.7 71.2 ± 23.6 0.25
Hb (g/dL) 13.4 ± 1.6 13.5 ± 1.6 0.51
Gender (n, %) 0.32
Female 319 (20.1%) 297 (18.71%)
Male 1268 (79.9%) 1290 (81.29%)
NYHA (n, %) 0.78
I 231 (14.56%) 230 (14.49%)
II 957 (60.3%) 944 (59.48%)
III 383 (24.13%) 401 (25.27%)
IV 16 (1.01%) 12 (0.76%)
Atrial ﬁbrillation (n, %) 244 (15.37%) 254 (16.06%) 0.60
ICD (n, %) 498 (31.38%) 512 (32.26%) 0.59
CRT (n, %) 188 (11.97%) 202 (12.86%) 0.45
Aetiology (n, %)
Idiopathic 572 (36.13%) 603 (38.09%)
Ischaemic 759 (47.95%) 747 (47.19%) 0.64
Valvular 83 (5.24%) 75 (4.74%)
Other 169 (10.68%) 158 (9.98%)
ACE inhibitors (n, %) 1175 (74.04%) 1179 (74.29%) 0.87
ARBs (n, %) 312 (19.66%) 303 (19.09%) 0.69
Diuretics (n, %) 1352 (85.19%) 1349 (85%) 0.88
Statins (n, %) 820 (51.67%) 822 (51.8%) 0.94
Allopurinol (n, %) 450 (28.36%) 482 (30.37%) 0.21
Beta-blockers (n, %) 1416 (89.22%) 1417 (89.29%) 0.95
Antiplatelets (n, %) 907 (57.15%) 931 (58.66%) 0.39
Oral anticoagulants (n, %) 425 (26.78%) 431 (27.16%) 0.81
Digitalis (n, %) 227 (14.3%) 220 (13.86%) 0.72
Amiodarone (n, %) 360 (22.68%) 401 (25.27%) 0.09
Potassium (meq/L) 4.3 ± 0.5 4.3 ± 0.5 0.64
Sodium (mmol/L) 139.5 ± 3 139.5 ± 3.1 0.99
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor
blockers; BMI, body mass index; CRT, cardiac resynchronization
therapy; Hb, haemoglobin; HR, heart rate; ICD, implantable
cardioverter deﬁbrillator; LVEF, ejection fraction; MDRD, Modiﬁca-
tion of Diet in Renal Disease; MRA, mineralocorticoid receptor an-
tagonists; NYHA, New York Heart Association; Peak VO2, oxygen
uptake at peak exercise; SBP, systolic blood pressure; VE/VCO2
slope, minute ventilation/carbon dioxide production relationship.
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pressure. MRA-treated patients never showed a better out-
come, as analysed through the study endpoint, compared
with MRA-untreated patients.
Discussion
The present study provides important insights into the long-
term effects of MRA treatment in real-life HFrEF patients.
When compared with MRA-untreated patients, MRA-treated
patients have a more severe HF, likely because of previous
guidelines indications and suggestions, which were guided
by RALES entry criteria and results. Indeed, the MECKI score
dataset includes patients enrolled during several years
starting from 1993. Notably, after performing propensity
score match so as to overwhelm HF severity differences, we
found that at 10 years’ follow-up MRA use does not emerge
as an independent predictor of long-term better or worse
survival assessed as the composite of cardiovascular death,
urgent heart transplantation or LVAD implantation.
These results were unexpected because the RALES,2 EPHE-
SUS,3 and EMPHASIS-HF4 trials all had demonstrated relevant
beneﬁts of the addition of MRA to an HF treatment regimen.
In the RALES trial, the MRA spironolactone, added to recom-
mended medical therapy, reduced the rates of death from any
cause and hospitalization for cardiovascular reasons among pa-
tients with HFrEF (in NYHA Class III or IV).2 The EPHESUS trial
showed that adding the selective MRA eplerenone to recom-
mended therapy in patients with acute myocardial infarction
complicated by left ventricular systolic dysfunction and HF de-
creased the rates of death from any cause and hospitalization
for cardiovascular reasons.3 Finally, in the EMPHASIS-HF,
eplerenone reduced the primary endpoint of cardiovascular
death or HF hospitalization and the secondary endpoint of all-
cause mortality in comparison with placebo when added to
evidence-based therapy among patients with HFrEF and mild
symptoms.4 According to these clinical trials, the usefulness of
MRA in HFrEF treatment is particularly relevant. In this regard,
it should be underlined that the RALES and EPHESUS were both
stopped ahead of time because an interim analysis determined
the efﬁcacy of MRA; consequently, the median follow-up of the
RALES, EPHESUS, and EMPHASIS-HF was 24, 16, and 21months,
respectively.2–4 In contrast, we showed in a sizable population
of HFrEF patients, followed for an average duration longer than
that of research trials, that MRA did not improve the present
study endpoint. Notably truncating the follow-up at 2 years as
in the RALES2or excluding patients with K+ > 5.0 meq/L, we
showed no endpoint differences between the MRA-treated
andMRA-untreated groups. Moreover, in none of the subgroup
analysis MRA treatment was associated with a better outcome.
In the real world, HF patients may be prone to serious HK
when taking the combination of MRA and angiotensin-
converting enzyme inhibitors in the presence of
co-morbidities like diarrhoea, pre-renal failure, renovascular
disease and diabetes mellitus.8 Indeed, an increase of in-
hospital death among HF patients was described also by
Juurlink’s group in a Canadian population study. In that pop-
ulation, the publication of RALES was associated with an in-
crease in spironolactone use and in the rates of hospital
admission for HK and subsequent in-hospital death among
HF patients.10 Similarly, another population study showed
that spironolactone use was not associated with improved
long-term survival in the general HF population.15 However,
the above-reported observations do not mean that
Figure 3 Kaplan–Meier analyses of study endpoint (cardiovascular death,
urgent heart transplant, or left ventricular assist device implantation)of
the mineralocorticoid receptor antagonist (MRA)-treated (MRA+) and
MRA-untreated (MRA) patients after propensity-score-matching analy-
sis: at 10 years’ follow-up, survival differences between MRA+ and MRA
patients reduced and statistical signiﬁcance was lost (P = 0.12). HR, haz-
ard ratio.
Table 3 Hazard ratios for mineralocorticoid receptor antagonists obtained with different analytical approaches
Analysis Hazard ratio 95% conﬁdence interval P
Multivariable Cox regression analysis (original dataset) 1.15 0.98 1.34 0.09
Cox regression using PS as a covariate (original dataset) 1.13 0.97 1.32 0.13
Cox regression stratiﬁed for PS (original dataset) 1.14 0.97 1.34 0.12
Unadjusted Cox regression (on PS matched data) 1.15 0.96 1.38 0.12
PS, propensity score.
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conclusions gained by the RALES trial are wrong; it is likely, in-
deed, that physicians may have prescribed inappropriately
high doses of spironolactone without monitoring potassium
levels closely or that they may have extended the RALES ﬁnd-
ings to patients who were not affected by left ventricular sys-
tolic dysfunction or with other co-morbidities, which might
have led to a reduced efﬁcacy of the drug or even to worsen-
ing of patients’ clinical condition.
It needs to be underlined that the MECKI score database is
continuously updated and new patients are added. However,
the dataset used for the present analysis included patients
enrolled from January 1993 to December 2015.Accordingly,
for a long time, MRA treatment was reserved to NYHA Class
III and Class IV patients. Indeed, it was only since 2011, with
the publication of EMPHASIS-HF,4 that the use of MRA was
also admitted in HF patients in NYHA Class II. It might repre-
sent an ‘indication bias’; however, also patients more recently
enrolled showed a similar HF severity distribution and prog-
nostic effects. Indeed, albeit guidelines’ changes, clinical
habits have a slow modiﬁcation rate. Notably, in the MECKI
score, treatment choice and drug dosage were independently
decided by local doctors. In clinical trials, eplerenone and
spironolactone retained their clinical beneﬁt, despite being
associated with more frequent WRF and HK. In the
EMPHASIS-HF and in the EPHESUS, eplerenone induced a
modest but statistically signiﬁcant decline in estimated glo-
merular ﬁltration rate and a rise in serum potassium.9,16
WRF and HK were also described in patients treated with
spironolactone in the RALES trial. In all clinical trials, WRF
and HK were not associated with an increased risk for
death.17
There are several possible reasons for our study’s failure
to detect the positive effect of MRA use on HFrEF survival
observed in randomized trial. First of all, this is a retrospec-
tive study, and we recognize that it cannot be compared
with the statistical power of the randomized controlled trials
mentioned above. Then, HK is likely a more common occur-
rence in clinical practice than it is in the carefully controlled
setting of RALES, EPHESUS, and EMPHASIS for several rea-
sons. Indeed, in the real world, a less compelling patient
follow-up compared with what happens in research trial is
frequently the case so that initial laboratory signs of body
organ deterioration may not be appreciated. Speciﬁcally,
outside the world of trials, physicians may not monitor po-
tassium levels closely in patients receiving MRA, alone or
in combination with other medications that contribute to
HK.18 In patients with severe HF enrolled in RALES, the
greatest change in potassium occurred within the ﬁrst
4 weeks after initiation of spironolactone.19 Therapeutic op-
timization with MRA is often conducted during ambulatory
visits or during hospitalization in referral HF hospitals far
from patients’ area. In these conditions, a direct close mon-
itoring is very difﬁcult. In addition, physician may neglect
baseline attributes that predispose patients to HK (e.g.
diabetes mellitus or renal diseases)20 and may overlook con-
ditions that develop during therapy (e.g. renal dysfunction).
Besides, some patients may purposefully increase their die-
tary potassium intake, as is often recommended during
treatment with diuretics such as furosemide.
Our study has some important limitations. Firstly, patients
were not randomized to MRA active treatment or placebo,
but it is an analysis of a large dataset of HFrEF patients
followed in several HF units. Consequently, the reasons be-
yond MRA treatment or non-treatment are unknown. Sec-
ondly, the analysis is based on HFrEF patients able to
perform a CPET, and this may result in selection of a popu-
lation not closely representative of a general population, in-
cluding subjects with worse HFrEF stages. Thirdly, it should
be considered that this analysis was performed considering
a static picture of the population at baseline without taking
into account the possible changes in treatments during
follow-up, carrying a possible prognostic association. Indeed,
during the long follow-up, MRA treatment might have been
added to treatment as recommended by guidelines.12 How-
ever, also when analysis was truncated at 2 years, MRA-
treated and MRA-untreated patients showed similar results.
Moreover, the dosage of MRA was not recorded, and we
cannot analyse any dose-related effect on prognosis, albeit
a high MRA dose is rarely prescribed. It is also recognized
that very few patients received eplerenone owing to the
only recent commercial availability of this drug in Italy so
that our results should not be extended to this speciﬁc
MRA. Moreover, we have not evaluated rehospitalization
rates, a study endpoint that was reported signiﬁcantly
reduced in a few MRA trials.21,22 Lastly, the results of this
study can only be applicable to HFrEF patients, as the role
of MRA in HF patients with preserved systolic function has
not been addressed.
In conclusion, this study shows that in the real world MRA
treatment is not associated with HFrEF patients’ survival
improvement and suggests that a strict adherence to the
inclusion criteria, dosing, and monitoring regimens used in
RALES, EPHESUS, and EMPHASIS-HF should be applied also
in clinical practice to realize the positive beneﬁt/risk ratio
achieved by MRA in the clinical trials. Further prospective
studies exploring long-term mortality may be interesting
and useful in the scope of therapy with MRA in HF.
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Cardiologico Monzino, IRCCS, Milano; Alessandro Ferraironi
from the Cardiology University Department, Heart Failure
Unit and Cardiopulmonary Laboratory Santo Spirito Hospital,
Roma; Francesca Pietrucci from Cardiologia Riabilitativa,
Azienda Ospedali Riuniti, Ancona; Gabriella Malfatto, Sergio
Caravita, and Elena Viganò from Istituto Auxologico Italiano;
Fabio Valente, Rossella Vastarella, Rita Gravino, Teo Roselli,
and Andrea Buono from Cardiologia SUN, Ospedale Monaldi
Napoli; Renata De Maria from CNR-Milano; Andrea
Passantino, Daniela Santoro, Saba Campanale, and Domenica
Caputo from Istituti Clinici Scientiﬁci Maugeri, Cassano delle
Murge; Donatella Bertipaglia from Istituti Clinici Scientiﬁci
Maugeri, Tradate; Marco Confalonieri, Emanuela Berton,
Elena Zambon, Marco Morosin from Ospedali Riuniti and
University of Trieste; Armando Ferraretti from the Depart-
ment of Cardiology, University of Foggia, Foggia; Chiara Minà
from the Department for the Treatment and Study of Cardio-
thoracic Diseases and Cardiothoracic Transplantation
IRCCS-ISMETT, Palermo; Elisa Battaia from the Department
of Cardiology, S. Chiara Hospital, Trento; Giovanni Marchese
from the Cardiac Rehabilitation Unit, Istituti Clinici Scientiﬁci
Maugeri, Milan; Annamaria Iorio from Ospedale Papa
Giovanni XXIII, Bergamo; and Luigi Pastormerlo from
Fondazione Gabriele Monasterio, CNR-Regione Toscana, Pisa.
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